Neurocrine Biosciences Q4 Adjusted EPS $1.54 Beats $1.15 Estimate, Sales $515.20M Miss $518.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 adjusted EPS of $1.54, surpassing the $1.15 estimate, marking a 33.91% beat and a 24.19% increase from last year. However, their Q4 sales of $515.20M fell short of the $518.13M estimate by 0.57%, despite being a 25.05% increase from the previous year.
February 07, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences reported a strong Q4 EPS of $1.54, beating estimates, but sales slightly missed expectations at $515.20M.
The significant beat on the EPS estimate and the year-over-year growth in earnings suggest a positive outlook for NBIX, likely leading to a short-term positive impact on the stock price. The slight miss on sales estimates may temper some of the enthusiasm, but the overall strong financial performance and growth trajectory are more likely to influence investor sentiment positively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100